Vivos Therapeutics Inc
NASDAQ:VVOS
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Vivos Therapeutics Inc
Operating Income
Vivos Therapeutics Inc
Operating Income Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
Vivos Therapeutics Inc
NASDAQ:VVOS
|
Operating Income
-$11.2m
|
CAGR 3-Years
17%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
N/A
|
|
|
Quest Diagnostics Inc
NYSE:DGX
|
Operating Income
$1.7B
|
CAGR 3-Years
9%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
4%
|
|
|
CVS Health Corp
NYSE:CVS
|
Operating Income
$10.5B
|
CAGR 3-Years
-14%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
1%
|
|
|
Cigna Corp
NYSE:CI
|
Operating Income
$10.3B
|
CAGR 3-Years
6%
|
CAGR 5-Years
4%
|
CAGR 10-Years
12%
|
|
|
Laboratory Corporation of America Holdings
NYSE:LH
|
Operating Income
$1.5B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
-13%
|
CAGR 10-Years
3%
|
|
|
Guardant Health Inc
NASDAQ:GH
|
Operating Income
-$437.2m
|
CAGR 3-Years
7%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
N/A
|
|
Vivos Therapeutics Inc
Glance View
Vivos Therapeutics, Inc. is a medical technology company which engages in the development and commercialization of treatment alternatives for patients with sleep disordered breathing (SDB). The company is headquartered in Highlands Ranch, Colorado and currently employs 158 full-time employees. The company went IPO on 2020-12-11. The firm is focused on the development and commercialization to dental practices of a patented oral appliance technology and related protocols called the Vivos System. The firm's Vivos System is a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for people with sleep disordered breathing (SDB), including mild-to-moderate obstructive sleep apnea (OSA). The Company’s business model is focused on dentists, and the Company’s program to train dentists and offer them other value-added services in connection with their ordering and use of the Vivos System for patients is called the Vivos Integrated Practice (VIP) program. Its primary product used in the Vivos System is the mRNA appliance, a specifically designed, custom oral appliance that is worn primarily in the evening hours and overnight and is available for adults.
See Also
What is Vivos Therapeutics Inc's Operating Income?
Operating Income
-11.2m
USD
Based on the financial report for Dec 31, 2024, Vivos Therapeutics Inc's Operating Income amounts to -11.2m USD.
What is Vivos Therapeutics Inc's Operating Income growth rate?
Operating Income CAGR 5Y
-1%
Over the last year, the Operating Income growth was 35%. The average annual Operating Income growth rates for Vivos Therapeutics Inc have been 17% over the past three years , -1% over the past five years .